

# Kwang-Hyub Han

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9077280/kwang-hyub-han-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

455  
papers

20,997  
citations

62  
h-index

130  
g-index

474  
ext. papers

24,889  
ext. citations

5.4  
avg, IF

6.52  
L-index

#	Paper	IF	Citations
455	Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2021</b> , 33, 885-893	2.2	3
454	Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study. <i>Digestive Diseases and Sciences</i> , <b>2021</b> , 66, 2427-2438	4	2
453	Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , <b>2021</b> , 27, 295-304	6.9	3
452	Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2021</b> , 147, 3123-3133	4.9	1
451	Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial. <i>Clinical and Molecular Hepatology</i> , <b>2021</b> , 27, 346-359	6.9	3
450	Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma. <i>Gut and Liver</i> , <b>2021</b> , 15, 420-429	4.8	1
449	Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT. <i>Journal of Gastroenterology</i> , <b>2021</b> , 56, 570-580	6.9	0
448	Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 4848-4858	12.9	8
447	Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials. <i>Gut and Liver</i> , <b>2021</b> , 15, 895-903	4.8	2
446	Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , <b>2021</b> , 62, 12-20	3	1
445	Epidemiological and Clinical History of Viral Hepatitis in Korea. <i>Infection and Chemotherapy</i> , <b>2021</b> , 53, 159-165	3.9	3
444	Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy. <i>Gut and Liver</i> , <b>2021</b> , 15, 117-127	4.8	8
443	Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients. <i>Journal of Korean Medical Science</i> , <b>2021</b> , 36, e105	4.7	0
442	Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study. <i>Clinical and Molecular Hepatology</i> , <b>2021</b> , 27, 125-135	6.9	1
441	Multidisciplinary Team Approaches for the Management of Hepatocellular Carcinoma <b>2021</b> , 277-283		
440	Entecavir and tenofovir on renal function in patients with hepatitis B virus-related hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 932-940	3.4	1
439	A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. <i>Liver Cancer</i> , <b>2020</b> , 9, 245-260	9.1	63

438	Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 196-204	6.1	16
437	High body mass index hinders fibrosis improvement in patients receiving long-term tenofovir therapy in hepatitis B virus-related cirrhosis. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 1119-1126	3.4	2
436	HKR3 regulates cell cycle through the inhibition of hTERT in hepatocellular carcinoma cell lines. <i>Journal of Cancer</i> , <b>2020</b> , 11, 2442-2452	4.5	4
435	Effects of transarterial chemoembolization on regulatory T cell and its subpopulations in patients with hepatocellular carcinoma. <i>Hepatology International</i> , <b>2020</b> , 14, 249-258	8.8	7
434	Efficacy and Safety of Liver-Directed Concurrent Chemoradiotherapy and Sequential Sorafenib for Advanced Hepatocellular Carcinoma: A Prospective Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2020</b> , 107, 106-115	4	10
433	A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea. <i>PLoS ONE</i> , <b>2020</b> , 15, e0232186	3.7	3
432	A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 855-862	13.4	32
431	Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase. <i>Clinical and Translational Gastroenterology</i> , <b>2020</b> , 11, e00140	4.2	9
430	Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2020</b> , 29, 832-837	4	17
429	CheckMate 459: Health-related quality of life (HRQoL) in a randomized, multicenter phase III study of nivolumab (NIVO) versus sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 483-483	2.2	11
428	Correlation of the grade of hepatic steatosis between controlled attenuation parameter and ultrasound in patients with fatty liver: a multi-center retrospective cohort study. <i>Korean Journal of Internal Medicine</i> , <b>2020</b> , 35, 1346-1353	2.5	1
427	Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion. <i>Journal of Hepatocellular Carcinoma</i> , <b>2020</b> , 7, 403-412	5.3	4
426	Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B. <i>Journal of Korean Medical Science</i> , <b>2020</b> , 35, e104	4.7	2
425	A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea. <i>Clinical and Molecular Hepatology</i> , <b>2020</b> , 26, 24-32	6.9	17
424	Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein level predicts recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection. <i>Clinical and Molecular Hepatology</i> , <b>2020</b> , 26, 33-44	6.9	11
423	Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study. <i>Gut and Liver</i> , <b>2020</b> , 14, 477-485	4.8	1
422	Sarcopenia Is Independently Associated with the Degree of Liver Fibrosis in Patients with Type 2 Diabetes Mellitus. <i>Gut and Liver</i> , <b>2020</b> , 14, 626-635	4.8	10
421	The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization. <i>Gut and Liver</i> , <b>2020</b> , 14, 765-774	4.8	8

4 <sup>20</sup>	Validation of the CAMD Score in Patients With Chronic Hepatitis B Virus Infection Receiving Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 693-699.e1	6.9	16
4 <sup>19</sup>	An observational study on long-term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 316-322	3.4	5
4 <sup>18</sup>	Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 167-228	18.8	120
4 <sup>17</sup>	Combined use of rosuvastatin and ezetimibe improves hepatic steatosis in patients with dyslipidemia. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2020</b> , 32, 1538-1544	2.2	2
4 <sup>16</sup>	Establishment and validation of a risk prediction model in patients with hepatocellular carcinoma treated with transarterial radioembolization. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2020</b> , 32, 739-747	2.2	2
4 <sup>15</sup>	Sarcopenia assessed using bioimpedance analysis is associated independently with significant liver fibrosis in patients with chronic liver diseases. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2020</b> , 32, 58-65	2.2	5
4 <sup>14</sup>	Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2020</b> , 32, 378-385	2.2	10
4 <sup>13</sup>	Advanced Liver Fibrosis Predicts Unfavorable Long-Term Prognosis in First-Ever Ischemic Stroke or Transient Ischemic Attack. <i>Cerebrovascular Diseases</i> , <b>2020</b> , 49, 474-480	3.2	5
4 <sup>12</sup>	Association between liver fibrosis and appendicular skeletal muscle mass during antiviral therapy in chronic hepatitis B. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 1338-1345	3.3	2
4 <sup>11</sup>	Liver-directed combined radiotherapy as a bridge to curative surgery in locally advanced hepatocellular carcinoma beyond the Milan criteria. <i>Radiotherapy and Oncology</i> , <b>2020</b> , 152, 1-7	5.3	7
4 <sup>10</sup>	Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 1217-1225	0.7	7
4 <sup>09</sup>	Fibrosis-4 index at diagnosis can predict all-cause mortality in patients with rheumatoid arthritis: A retrospective monocentric study. <i>Modern Rheumatology</i> , <b>2020</b> , 30, 70-77	3.3	11
4 <sup>08</sup>	Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 457-467.e21	6.9	27
4 <sup>07</sup>	Dose escalation in radiotherapy for incomplete transarterial chemoembolization of hepatocellular carcinoma. <i>Strahlentherapie Und Onkologie</i> , <b>2020</b> , 196, 132-141	4.3	9
4 <sup>06</sup>	Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 584-595	0.7	24
4 <sup>05</sup>	A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea <b>2020</b> , 15, e0232186		
4 <sup>04</sup>	A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea <b>2020</b> , 15, e0232186		
4 <sup>03</sup>	A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea <b>2020</b> , 15, e0232186		

402	A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea <b>2020</b> , 15, e0232186		
401	High Risk of Hepatocellular Carcinoma Development in Fibrotic Liver: Role of the Hippo-YAP/TAZ Signaling Pathway. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	17
400	Staged partial hepatectomy versus transarterial chemoembolization for the treatment of spontaneous hepatocellular carcinoma rupture: a multicenter analysis in Korea. <i>Annals of Surgical Treatment and Research</i> , <b>2019</b> , 96, 275-282	2	9
399	Long-term Outcomes of Antiviral Therapy in Patients With Advanced Chronic HBV Infection. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2811-2813.e1	6.9	6
398	Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis. <i>Digestive Diseases and Sciences</i> , <b>2019</b> , 64, 3660-3668	4	6
397	Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cells. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 289-300	13.4	22
396	Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2808-2810.e2	6.9	9
395	Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma. <i>BMC Cancer</i> , <b>2019</b> , 19, 363	4.8	7
394	External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy. <i>Liver International</i> , <b>2019</b> , 39, 1624-1630	7.9	22
393	Dose escalation by intensity modulated radiotherapy in liver-directed concurrent chemoradiotherapy for locally advanced BCLC stage C hepatocellular carcinoma. <i>Radiotherapy and Oncology</i> , <b>2019</b> , 133, 1-8	5.3	18
392	Predictors of Discordance in the Assessment of Skeletal Muscle Mass between Computed Tomography and Bioimpedance Analysis. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	4
391	Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Cancers</i> , <b>2019</b> , 11,	6.6	24
390	Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection. <i>PLoS ONE</i> , <b>2019</b> , 14, e0214613	3.7	4
389	A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 456-464	13.4	91
388	Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 1850-1859.e4	6.9	26
387	Liver Fibrosis, Not Steatosis, Associates with Long-Term Outcomes in Ischaemic Stroke Patients. <i>Cerebrovascular Diseases</i> , <b>2019</b> , 47, 32-39	3.2	16
386	Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals. <i>Scientific Reports</i> , <b>2019</b> , 9, 2508	4.9	10
385	Alpha-Fetoprotein, Des-Gamma-Carboxy Prothrombin, and Modified RECIST Response as Predictors of Survival after Transarterial Radioembolization for Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , <b>2019</b> , 30, 1194-1200.e1	2.4	10

384	Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation. <i>Cancer Medicine</i> , <b>2019</b> , 8, 5023-5032	4.8	20
383	Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma. <i>British Journal of Cancer</i> , <b>2019</b> , 121, 218-221	8.7	12
382	Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , <b>2019</b> , 54, 1283-1290	2.4	8
381	Changes in real-life practice for hepatocellular carcinoma patients in the Republic of Korea over a 12-year period: A nationwide random sample study. <i>PLoS ONE</i> , <b>2019</b> , 14, e0223678	3.7	9
380	Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 186-186	2.2	21
379	Differences in presentation and management patterns in patients with hepatocellular carcinoma (HCC): Data from HCC registry in Asia.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 229-229	2.2	1
378	Safety and efficacy of lenvatinib by starting dose (8 mg or 12 mg) based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 316-316	2.2	1
377	Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 317-317	2.2	18
376	Serum PD-1 Levels Change with Immunotherapy Response but Do Not Predict Prognosis in Patients with Hepatocellular Carcinoma. <i>Journal of Liver Cancer</i> , <b>2019</b> , 19, 108-116	0.7	4
375	Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir. <i>Clinical and Molecular Hepatology</i> , <b>2019</b> , 25, 283-293	6.9	16
374	Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , <b>2019</b> , 25, 390-399	6.9	14
373	Conditional Survival Estimates Improve Over Time for Patients with Hepatocellular Carcinoma: An Analysis for Nationwide Korea Cancer Registry Database. <i>Cancer Research and Treatment</i> , <b>2019</b> , 51, 1347-1356	5.2	4
372	Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status. <i>Gut and Liver</i> , <b>2019</b> , 13, 197-205	4.8	9
371	Multicenter Retrospective Risk Assessment of Esophageal Variceal Bleeding in Patients with Cirrhosis: An Acoustic Radiation Force Impulse Elastography-Based Prediction Model. <i>Gut and Liver</i> , <b>2019</b> , 13, 206-214	4.8	1
370	Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma. <i>Radiotherapy and Oncology</i> , <b>2019</b> , 131, 81-87	5.3	41
369	The Influence of Histologic Inflammation on the Improvement of Liver Stiffness Values Over 1 and 3 Years. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	3
368	Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals. <i>Clinical and Translational Gastroenterology</i> , <b>2019</b> , 10, e00036	4.2	10
367	Predictive validation of qualitative fibrosis staging in patients with chronic hepatitis B on antiviral therapy. <i>Scientific Reports</i> , <b>2019</b> , 9, 15628	4.9	3

366	Long-term Efficacy of Tenofovir Disoproxil Fumarate Monotherapy for Multidrug-Resistant Chronic HBV infection. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 1348-1355.e2	6.9	10
365	Phase I/II trial of helical IMRT-based stereotactic body radiotherapy for hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 445-451	3.3	19
364	Fibrosis-matched outcomes between chronic hepatitis B patients with drug-induced virological response and inactive carriers. <i>Liver International</i> , <b>2019</b> , 39, 81-89	7.9	1
363	Subclinical but significant liver fibrosis in patients with ANCA-associated vasculitis. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 117, 26-31	2.2	1
362	Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib. <i>Liver International</i> , <b>2018</b> , 38, 1655-1663	7.9	13
361	Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. <i>Lancet, The</i> , <b>2018</b> , 391, 1163-1173	40	1995
360	Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 503-510	4	16
359	Feasibility of dynamic risk prediction for hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Liver International</i> , <b>2018</b> , 38, 676-686	7.9	20
358	Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 1429-1437	3.4	14
357	Effects of Virologic Response to Treatment on Short- and Long-term Outcomes of Patients With Chronic Hepatitis B Virus Infection and Decompensated Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 1954-1963.e3	6.9	30
356	Downstaging with Localized Concurrent Chemoradiotherapy Can Identify Optimal Surgical Candidates in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 3308-3315	3.1	23
355	Independent imaging review (IIR) results in a phase 3 trial of lenvatinib (LEN) versus sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 345-345	2.2	1
354	Treatment of Hepatocellular Carcinoma With Lenvatinib. <i>Gastroenterology and Hepatology</i> , <b>2018</b> , 14, 662-664	0.7	2
353	Combination of Transient Elastography and an Enhanced Liver Fibrosis Test to Assess the Degree of Liver Fibrosis in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , <b>2018</b> , 12, 190-200	4.8	6
352	Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety. <i>Gut and Liver</i> , <b>2018</b> , 12, 324-330	4.8	6
351	Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study. <i>CardioVascular and Interventional Radiology</i> , <b>2018</b> , 41, 459-465	2.7	9
350	The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C. <i>Liver International</i> , <b>2018</b> , 38, 1179-1187	7.9	16
349	Switching from tenofovir and nucleoside analogue therapy to tenofovir monotherapy in virologically suppressed chronic hepatitis B patients with antiviral resistance. <i>Journal of Medical Virology</i> , <b>2018</b> , 90, 497-502	19.7	5

348	Serotonin signals through a gut-liver axis to regulate hepatic steatosis. <i>Nature Communications</i> , <b>2018</b> , 9, 4824	17.4	58
347	HBsAg-negative and anti-HBc-positive in eosinophilic granulomatosis with polyangiitis: a retrospective pilot study. <i>Rheumatology International</i> , <b>2018</b> , 38, 1531-1538	3.6	4
346	Cell culture-adaptive mutations of NS5A affect replication of hepatitis C virus differentially depending on the viral genotypes. <i>Journal of Medical Virology</i> , <b>2017</b> , 89, 146-152	19.7	3
345	NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 910-918	13.4	165
344	Liver fibrosis assessed with transient elastography is an independent risk factor for ischemic stroke. <i>Atherosclerosis</i> , <b>2017</b> , 260, 156-162	3.1	32
343	Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis. <i>Hepatology International</i> , <b>2017</b> , 11, 268-276	8.8	18
342	Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir. <i>Liver International</i> , <b>2017</b> , 37, 1788-1795	7.9	31
341	Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. <i>Hepatology International</i> , <b>2017</b> , 11, 317-370	8.8	955
340	Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , <b>2017</b> , 62, 2150-2158	4.58	13
339	Prognostic Value of FDG Uptake of Portal Vein Tumor Thrombosis in Patients With Locally Advanced Hepatocellular Carcinoma. <i>Clinical Nuclear Medicine</i> , <b>2017</b> , 42, e35-e40	1.7	10
338	Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: AI Propensity Score Matching Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2017</b> , 99, 396-406	4	12
337	Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization. <i>Hepatology International</i> , <b>2017</b> , 11, 292-299	8.8	5
336	Improvement of Liver Fibrosis after Long-Term Antiviral Therapy Assessed by Fibroscan in Chronic Hepatitis B Patients With Advanced Fibrosis. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 882-891	0.7	33
335	Sequence analysis and functional characterization of full-length hepatitis B virus genomes from Korean cirrhotic patients with or without liver cancer. <i>Virus Research</i> , <b>2017</b> , 235, 86-95	6.4	14
334	Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 1022-1030	13.4	415
333	Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts the risk of HBV-related liver cancer development. <i>Liver International</i> , <b>2017</b> , 37, 879-887	7.9	29
332	Obesity is more closely related with hepatic steatosis and fibrosis measured by transient elastography than metabolic health status. <i>Metabolism: Clinical and Experimental</i> , <b>2017</b> , 66, 23-31	12.7	46
331	Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis. <i>Gut and Liver</i> , <b>2017</b> , 11, 828-834	4.8	16



330	Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea. <i>PLoS ONE</i> , <b>2017</b> , 12, e0167770	3.7	23
329	Transforming Growth Factor- $\beta$ Promotes Liver Tumorigenesis in Mice via Up-regulation of Snail. <i>Gastroenterology</i> , <b>2017</b> , 153, 1378-1391.e6	13.3	49
328	Long-Term Follow-Up of Patients After Autologous Bone Marrow Cell Infusion for Decompensated Liver Cirrhosis. <i>Cell Transplantation</i> , <b>2017</b> , 26, 1059-1066	4	9
327	Less Fibrotic Burden Differently Affects the Long-Term Outcomes of Hepatocellular Carcinoma after Curative Resection. <i>Oncology</i> , <b>2017</b> , 93, 224-232	3.6	3
326	Risk stratification for locally advanced hepatocellular carcinoma using pretreatment alpha-fetoprotein and F-fluoro-2-deoxyglucose positron emission tomography. <i>Liver International</i> , <b>2017</b> , 37, 592-599	7.9	4
325	Using transient elastography to predict hepatocellular carcinoma recurrence after radiofrequency ablation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2017</b> , 32, 1079-1086	4	14
324	Gamma-glutamyl transpeptidase-to-platelet ratio is an independent predictor of hepatitis B virus-related liver cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2017</b> , 32, 1221-1229	4	25
323	Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2017</b> , 32, 487-496	4	24
322	Durability of the virological response after lamivudine discontinuation in lamivudine-resistant patients with a complete virological response after lamivudine and adefovir combination therapy. <i>Journal of Medical Virology</i> , <b>2017</b> , 89, 85-90	19.7	5
321	Effect of S267F variant of NTCP on the patients with chronic hepatitis B. <i>Scientific Reports</i> , <b>2017</b> , 7, 17634	4.9	13
320	Validation of risk prediction models for the development of HBV-related HCC: a retrospective multi-center 10-year follow-up cohort study. <i>Oncotarget</i> , <b>2017</b> , 8, 113213-113224	3.3	16
319	Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4001-4001	2.2	45
318	The relationship between visceral obesity and hepatic steatosis measured by controlled attenuation parameter. <i>PLoS ONE</i> , <b>2017</b> , 12, e0187066	3.7	11
317	Dickkopf-1 induces angiogenesis via VEGF receptor 2 regulation independent of the Wnt signaling pathway. <i>Oncotarget</i> , <b>2017</b> , 8, 58974-58984	3.3	12
316	Conditional survival estimate in patients with Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy with/without concurrent radiotherapy. <i>Oncotarget</i> , <b>2017</b> , 8, 79914-79926	3.3	5
315	Acute hepatitis A, B and C but not D is still prevalent in Mongolia: a time trend analysis. <i>Clinical and Molecular Hepatology</i> , <b>2017</b> , 23, 147-153	6.9	6
314	Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation. <i>Gut and Liver</i> , <b>2017</b> , 11, 693-701	4.8	4
313	Efficacy and safety of localized concurrent chemoradiation therapy and sorafenib sequential therapy in advanced hepatocellular carcinoma: A prospective phase II trial.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e15678-e15678	2.2	

312	Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. <i>Scandinavian Journal of Gastroenterology</i> , <b>2016</b> , 51, 344-53 <sup>3,4</sup>	53.4	52
311	Knockdown of HIF-1 $\alpha$ and IL-8 induced apoptosis of hepatocellular carcinoma triggers apoptosis of vascular endothelial cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , <b>2016</b> , 21, 85-95 <sup>5,4</sup>	5.4	13
310	Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model. <i>Liver International</i> , <b>2016</b> , 36, 92-9	7.9	41
309	No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 63, 1202-1204	11.6	45
308	Development of a transgenic mouse model of hepatocellular carcinoma with a liver fibrosis background. <i>BMC Gastroenterology</i> , <b>2016</b> , 16, 13	3	15
307	Cryoablation of Hepatocellular Carcinoma with High-Risk for Percutaneous Ablation: Safety and Efficacy. <i>CardioVascular and Interventional Radiology</i> , <b>2016</b> , 39, 1447-54	2.7	24
306	Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011). <i>Hepatology</i> , <b>2016</b> , 63, 776-86	11.2	175
305	Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score. <i>Liver International</i> , <b>2016</b> , 36, 100-7	7.9	51
304	Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 1647-1656.e6	6.9	29
303	Incidence and risk factors of delayed postpolypectomy bleeding in patients with chronic liver disease. <i>Scandinavian Journal of Gastroenterology</i> , <b>2016</b> , 51, 618-24	2.4	13
302	Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients. <i>Journal of Gastroenterology</i> , <b>2016</b> , 51, 830-9	6.9	61
301	Hepatic expression of Sonic Hedgehog induces liver fibrosis and promotes hepatocarcinogenesis in a transgenic mouse model. <i>Journal of Hepatology</i> , <b>2016</b> , 64, 618-27	13.4	65
300	Noninvasive Prediction of Erosive Esophagitis Using a Controlled Attenuation Parameter (CAP)-Based Risk Estimation Model. <i>Digestive Diseases and Sciences</i> , <b>2016</b> , 61, 507-16	4	2
299	The effect of radiotherapy in liver-confined but non-resectable Barcelona Clinic Liver Cancer stage C large hepatocellular carcinoma. <i>Oncotarget</i> , <b>2016</b> , 7, 62715-62725	3.3	3
298	Phase I dose escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma. <i>Oncotarget</i> , <b>2016</b> , 7, 40756-40766	3.3	36
297	Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study). <i>Clinical and Molecular Hepatology</i> , <b>2016</b> , 22, 443-449	6.9	7
296	Clinical Benefit of Hepatic Arterial Infusion Concurrent Chemoradiotherapy in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. <i>Cancer Research and Treatment</i> , <b>2016</b> , 48, 190-7	5.2	13
295	Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data. <i>Cancer Research and Treatment</i> , <b>2016</b> , 48, 1243-1252	5.2	17

294	Factors Influencing the Diagnostic Accuracy of Acoustic Radiation Force Impulse Elastography in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , <b>2016</b> , 10, 275-82	4.8	14
293	Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response. <i>Gut and Liver</i> , <b>2016</b> , 10, 429-36	4.8	11
292	Hepatitis C Virus and Antiviral Drug Resistance. <i>Gut and Liver</i> , <b>2016</b> , 10, 890-895	4.8	12
291	Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy. <i>Yonsei Medical Journal</i> , <b>2016</b> , 57, 1276-81	3	25
290	The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter. <i>Yonsei Medical Journal</i> , <b>2016</b> , 57, 885-92	3	26
289	Angled Cool-Tip Electrode for Radiofrequency Ablation of Small Superficial Subcapsular Tumors in the Liver: A Feasibility Study. <i>Korean Journal of Radiology</i> , <b>2016</b> , 17, 742-9	6.9	6
288	Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C. <i>Journal of Korean Medical Science</i> , <b>2016</b> , 31, 1431-7	4.7	5
287	Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , <b>2016</b> , 11, e0157358	3.7	44
286	Transient Elastography is Superior to FIB-4 in Assessing the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. <i>Medicine (United States)</i> , <b>2016</b> , 95, e3434	1.8	10
285	Risk Assessment of Hepatocellular Carcinoma Using Transient Elastography Vs. Liver Biopsy in Chronic Hepatitis B Patients Receiving Antiviral Therapy. <i>Medicine (United States)</i> , <b>2016</b> , 95, e2985	1.8	17
284	Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study. <i>Liver International</i> , <b>2016</b> , 36, 1108-15	7.9	18
283	Reply. <i>Hepatology</i> , <b>2016</b> , 63, 672-3	11.2	
282	Transgenic mouse models generated by hydrodynamic transfection for genetic studies of liver cancer and preclinical testing of anti-cancer therapy. <i>International Journal of Cancer</i> , <b>2016</b> , 138, 1601-8	7.5	15
281	Prediction of virologic response to tenofovir mono-rescue therapy for multidrug resistant chronic hepatitis B. <i>Journal of Medical Virology</i> , <b>2016</b> , 88, 1027-34	19.7	8
280	The clinical implication of single nucleotide polymorphisms in deoxycytidine kinase in chronic hepatitis B patients treated with lamivudine. <i>Journal of Medical Virology</i> , <b>2016</b> , 88, 820-7	19.7	1
279	Use of Wisteria Floribunda Agglutinin-Positive Human Mac-2 Binding Protein in Assessing Risk of Hepatocellular Carcinoma Due to Hepatitis B Virus. <i>Medicine (United States)</i> , <b>2016</b> , 95, e3328	1.8	24
278	Subclassification of Barcelona Clinic Liver Cancer B and C hepatocellular carcinoma: A cohort study of the multicenter registry database. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2016</b> , 31, 842-7	4	17
277	A 96-week randomized trial of switching to entecavir in patients who achieved virological suppression on lamivudine therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2016</b> , 31, 865-71	4	2

276	A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. <i>Hepatology International</i> , <b>2016</b> , 10, 947-955	8.8	15
275	Clinical predictors of silent but substantial liver fibrosis in primary Sjogren's syndrome. <i>Modern Rheumatology</i> , <b>2016</b> , 26, 576-82	3.3	2
274	Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality. <i>Hepatology International</i> , <b>2016</b> , 10, 883-892	8.8	24
273	An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys): TRACES Study. <i>Medicine (United States)</i> , <b>2016</b> , 95, e3026	1.8	7
272	A phase 3b study of sofosbuvir plus ribavirin in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus. <i>Journal of Viral Hepatitis</i> , <b>2016</b> , 23, 358-65	3.4	24
271	Outcome of adefovir add-on lamivudine rescue therapy of up to 5 years in patients with lamivudine-resistant chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2016</b> , 31, 241-7	4	7
270	Liver stiffness-based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: comparison with histological fibrosis. <i>Liver International</i> , <b>2015</b> , 35, 1054-62	7.9	28
269	Reimbursement policies in the Asia-Pacific for chronic hepatitis B. <i>Hepatology International</i> , <b>2015</b> , 9, 43-51	3.8	17
268	Prevention of hepatocellular carcinoma: beyond hepatitis B vaccination. <i>Seminars in Oncology</i> , <b>2015</b> , 42, 316-28	5.5	14
267	Liver cancer: Approaching a personalized care. <i>Journal of Hepatology</i> , <b>2015</b> , 62, S144-56	13.4	175
266	Normal controlled attenuation parameter values: a prospective study of healthy subjects undergoing health checkups and liver donors in Korea. <i>Digestive Diseases and Sciences</i> , <b>2015</b> , 60, 234-42	4	11
265	The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis. <i>Annals of Nuclear Medicine</i> , <b>2015</b> , 29, 400-8	2.5	22
264	Analysis of miRNA expression patterns in human and mouse hepatocellular carcinoma cells. <i>Hepatology Research</i> , <b>2015</b> , 45, 1331-40	5.1	6
263	Accuracy of transient elastography in assessing liver fibrosis in chronic viral hepatitis: A multicentre, retrospective study. <i>Liver International</i> , <b>2015</b> , 35, 2246-55	7.9	56
262	Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2015</b> , 76, 257-67	3.5	4
261	Prognostic role of magnetic resonance imaging vs. computed tomography for hepatocellular carcinoma undergoing chemoembolization. <i>Liver International</i> , <b>2015</b> , 35, 1722-30	7.9	13
260	Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008-2011). <i>Journal of Hepatology</i> , <b>2015</b> , 63, 486-93	13.4	186
259	Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology</i> , <b>2015</b> , 16, 1344-54	21.7	553

258	Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin. <i>Digestive Diseases and Sciences</i> , <b>2015</b> , 60, 573-81	4.1	29
257	Prognostic value of the combined use of transient elastography and fibrotest in patients with chronic hepatitis B. <i>Liver International</i> , <b>2015</b> , 35, 455-62	7.9	17
256	Transgenic mouse model expressing P53(R172H), luciferase, EGFP, and KRAS(G12D) in a single open reading frame for live imaging of tumor. <i>Scientific Reports</i> , <b>2015</b> , 5, 8053	4.9	7
255	Factors associated with significant liver fibrosis assessed using transient elastography in general population. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 1158-66	5.6	34
254	Clonal evolution of multidrug resistant hepatitis B virus during entecavir rescue therapy. <i>Liver International</i> , <b>2015</b> , 35, 2370-83	7.9	2
253	Hepatic fibrosis assessed using transient elastography independently associated with coronary artery calcification. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 1536-42	4	17
252	Radioembolization With Yttrium-90 Resin Microspheres in Hepatocellular Carcinoma: A Multicenter Prospective Study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2015</b> , 38, 495-501	2.7	31
251	Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy. <i>Hepatology</i> , <b>2015</b> , 62, 1757-66	11.2	73
250	Early Ectoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib. <i>Journal of Hepatocellular Carcinoma</i> , <b>2015</b> , 2, 39-47	5.3	16
249	Use of transient elastography to predict de novo recurrence after radiofrequency ablation for hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , <b>2015</b> , 8, 347-56	4.4	18
248	A novel model to predict esophageal varices in patients with compensated cirrhosis using acoustic radiation force impulse elastography. <i>PLoS ONE</i> , <b>2015</b> , 10, e0121009	3.7	24
247	Relationship between Cerebral Microbleeds and Liver Stiffness Determined by Transient Elastography. <i>PLoS ONE</i> , <b>2015</b> , 10, e0139227	3.7	13
246	Serum Dickkopf-1 as a Biomarker for the Diagnosis of Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , <b>2015</b> , 56, 1296-306	3	25
245	Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2015</b> , 9, 335-48	4.2	43
244	Inter-observer variability of response evaluation criteria for hepatocellular carcinoma treated with chemoembolization. <i>Digestive and Liver Disease</i> , <b>2015</b> , 47, 682-8	3.3	5
243	Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 1304-10	13.4	108
242	Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment. <i>Liver International</i> , <b>2015</b> , 35, 1103-15	7.9	49
241	Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 526-32	13.4	38

240	Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis. <i>Hepatology</i> , <b>2015</b> , 61, 1809-20	11.2	95
239	Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis. <i>Hepatology</i> , <b>2015</b> , 61, 1851-9	11.2	100
238	Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 1024-31	4	9
237	Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease. <i>Clinical and Molecular Hepatology</i> , <b>2015</b> , 21, 279-86	6.9	53
236	Comparison of the Effects of Telbivudine and Entecavir Treatment on Estimated Glomerular Filtration Rate in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , <b>2015</b> , 9, 776-83	4.8	9
235	Early radiotherapy versus late radiotherapy after incomplete transarterial chemoembolization in hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 459-459	2.2	
234	Disease duration and Medsger's severity score are associated with significant liver fibrosis in patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, S68-74	2.2	4
233	Diffusion and perfusion MRI prediction of progression-free survival in patients with hepatocellular carcinoma treated with concurrent chemoradiotherapy. <i>Journal of Magnetic Resonance Imaging</i> , <b>2014</b> , 39, 286-92	5.6	17
232	Inhibition of tumour angiogenesis and growth by small hairpin HIF-1 $\alpha$ and IL-8 in hepatocellular carcinoma. <i>Liver International</i> , <b>2014</b> , 34, 632-42	7.9	25
231	Histological subclassification of cirrhosis can predict recurrence after curative resection of hepatocellular carcinoma. <i>Liver International</i> , <b>2014</b> , 34, 1008-17	7.9	35
230	Therapeutic benefit of radiotherapy in huge ( $\geq 10$ cm) unresectable hepatocellular carcinoma. <i>Liver International</i> , <b>2014</b> , 34, 784-94	7.9	22
229	Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2014</b> , 29, 1005-11	4	15
228	Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir. <i>Liver International</i> , <b>2014</b> , 34, 1216-23	7.9	27
227	Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy. <i>American Journal of Gastroenterology</i> , <b>2014</b> , 109, 1241-9	0.7	89
226	Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries. <i>Hepatology International</i> , <b>2014</b> , 8, 382-94	8.8	9
225	Lesson from 610 liver resections of hepatocellular carcinoma in a single center over 10 years. <i>World Journal of Surgical Oncology</i> , <b>2014</b> , 12, 192	3.4	13
224	Impact of spontaneous hepatocellular carcinoma rupture on recurrence pattern and long-term surgical outcomes after partial hepatectomy. <i>World Journal of Surgery</i> , <b>2014</b> , 38, 2070-8	3.3	31
223	Improved oncologic outcomes with image-guided intensity-modulated radiation therapy using helical tomotherapy in locally advanced hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2014</b> , 140, 1595-605	4.9	32

222	Surgical resection after down-staging of locally advanced hepatocellular carcinoma by localized concurrent chemoradiotherapy. <i>Annals of Surgical Oncology</i> , <b>2014</b> , 21, 3646-53	3.1	41
221	Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. <i>Gastroenterology</i> , <b>2014</b> , 146, 442-52.e1	13.3	101
220	Effective biliary drainage and proper treatment improve outcomes of hepatocellular carcinoma with obstructive jaundice. <i>Gut and Liver</i> , <b>2014</b> , 8, 526-35	4.8	9
219	New susceptibility and resistance HLA-DP alleles to HBV-related diseases identified by a trans-ethnic association study in Asia. <i>PLoS ONE</i> , <b>2014</b> , 9, e86449	3.7	28
218	Use of the delta neutrophil index as a prognostic factor of mortality in patients with spontaneous bacterial peritonitis: implications of a simple and useful marker. <i>PLoS ONE</i> , <b>2014</b> , 9, e86884	3.7	22
217	Liver stiffness value-based risk estimation of late recurrence after curative resection of hepatocellular carcinoma: development and validation of a predictive model. <i>PLoS ONE</i> , <b>2014</b> , 9, e99167	3.7	18
216	Casein kinase II inhibitor enhances production of infectious genotype 1a hepatitis C virus (H77S). <i>PLoS ONE</i> , <b>2014</b> , 9, e113938	3.7	7
215	Prognostic indicators for acute liver failure development and mortality in patients with hepatitis A: consecutive case analysis. <i>Yonsei Medical Journal</i> , <b>2014</b> , 55, 953-9	3	4
214	The efficacy of endoscopic palliation of obstructive jaundice in hepatocellular carcinoma. <i>Yonsei Medical Journal</i> , <b>2014</b> , 55, 1267-72	3	6
213	Non-invasive prediction of development of hepatocellular carcinoma using transient elastography in patients with chronic liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2014</b> , 8, 501-11	4.2	7
212	Individual prediction model for lamivudine treatment response in hepatitis B virus e antigen-positive chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2014</b> , 29, 1049-55	4	4
211	Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2014</b> , 29, 1463-9	4	23
210	Clinical usefulness of double biomarkers AFP and PIVKA-II for subdividing prognostic groups in locally advanced hepatocellular carcinoma. <i>Liver International</i> , <b>2014</b> , 34, 313-21	7.9	16
209	Maintaining remission in lamivudine-resistant patients with a virological response to adefovir add-on lamivudine after stopping lamivudine therapy. <i>Liver International</i> , <b>2014</b> , 34, 1543-9	7.9	10
208	Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. <i>Gut</i> , <b>2014</b> , 63, 996-1004	19.2	55
207	Risk assessment of clinical outcomes in Asian patients with chronic hepatitis B using enhanced liver fibrosis test. <i>Hepatology</i> , <b>2014</b> , 60, 1911-9	11.2	33
206	Pre-S mutations of hepatitis B virus affect genome replication and expression of surface antigens. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2014</b> , 29, 843-50	4	7
205	Risk assessment of liver-related events using transient elastography in patients with chronic hepatitis B receiving entecavir. <i>Journal of Clinical Gastroenterology</i> , <b>2014</b> , 48, 272-8	3	22

204	Hepatocellular carcinoma specific graded prognostic assessment can predict outcomes for patients with brain metastases from hepatocellular carcinoma. <i>Journal of Neuro-Oncology</i> , <b>2014</b> , 120, 199-207	4.8	13
203	Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. <i>Liver International</i> , <b>2014</b> , 34, 102-9	7.9	113
202	STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC). <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4006-4006	2.2	28
201	A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS4153-TPS4153	2.2	9
200	Hepatitis B viral load to predict survival of HCC patients treated with sorafenib.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 188-188	2.2	1
199	Dynamics of the liver stiffness value using transient elastography during the perioperative period in patients with valvular heart disease. <i>PLoS ONE</i> , <b>2014</b> , 9, e92795	3.7	15
198	Factors affecting the accuracy of controlled attenuation parameter (CAP) in assessing hepatic steatosis in patients with chronic liver disease. <i>PLoS ONE</i> , <b>2014</b> , 9, e98689	3.7	30
197	Silencing of hypoxia-inducible factor-1 induces anti-tumor effects in hepatoma cell lines under tumor hypoxia. <i>PLoS ONE</i> , <b>2014</b> , 9, e103304	3.7	9
196	Characteristics and Survival of Korean Patients with Hepatocellular Carcinoma: A Nationwide Random Sample Study. <i>Journal of Liver Cancer</i> , <b>2014</b> , 14, 97-107	0.7	2
195	Spontaneous HBsAg loss in Korean patients: relevance of viral genotypes, S gene mutations, and covalently closed circular DNA copy numbers. <i>Clinical and Molecular Hepatology</i> , <b>2014</b> , 20, 251-60	6.9	6
194	Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort. <i>Clinical and Molecular Hepatology</i> , <b>2014</b> , 20, 261-6	6.9	10
193	Emerging therapies for hepatitis C. <i>Gut and Liver</i> , <b>2014</b> , 8, 471-9	4.8	30
192	Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region. <i>Journal of Gastroenterology</i> , <b>2013</b> , 48, 681-8	6.9	40
191	Early predictor of mortality due to irreversible posthepatectomy liver failure in patients with hepatocellular carcinoma. <i>World Journal of Surgery</i> , <b>2013</b> , 37, 1028-33	3.3	15
190	Combined effects of an antioxidant and caspase inhibitor on the reversal of hepatic fibrosis in rats. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , <b>2013</b> , 18, 1481-91	5.4	12
189	Clinical application of liver stiffness measurement using transient elastography: a surgical perspective. <i>Digestion</i> , <b>2013</b> , 88, 258-65	3.6	17
188	Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 826-34	7.5	65
187	Prognostic value of E-fetoprotein and des-E-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. <i>BMC Cancer</i> , <b>2013</b> , 13, 5	4.8	48



186	Non-O1, Non-O139 Vibrio cholerae Septicemia after Acupuncture. <i>The Ewha Medical Journal</i> , <b>2013</b> , 36, S22	0.1	4
185	Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. <i>Oncology</i> , <b>2013</b> , 84, 311-8	3.6	114
184	Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 7671-9	5.6	6
183	Clinical factors related to recurrence after hepatic arterial concurrent chemoradiotherapy for advanced but liver-confined hepatocellular carcinoma. <i>Journal of Radiation Research</i> , <b>2013</b> , 54, 1069-77	2.4	8
182	Partial virological response to adefovir add-on lamivudine rescue therapy in patients with lamivudine-resistant chronic hepatitis B. <i>Digestion</i> , <b>2013</b> , 87, 196-203	3.6	2
181	Survival of hepatocellular carcinoma patients may be improved in surveillance interval not more than 6 months compared with more than 6 months: a 15-year prospective study. <i>Journal of Clinical Gastroenterology</i> , <b>2013</b> , 47, 538-44	3	38
180	Prognostic significance of the worst grade in hepatocellular carcinoma with heterogeneous histologic grades of differentiation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2013</b> , 28, 1384-90	4	41
179	Normal enhanced liver fibrosis (ELF) values in apparently healthy subjects undergoing a health check-up and in living liver donors in South Korea. <i>Liver International</i> , <b>2013</b> , 33, 706-13	7.9	13
178	A nationwide seroepidemiology of hepatitis C virus infection in South Korea. <i>Liver International</i> , <b>2013</b> , 33, 586-94	7.9	68
177	Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 1503-11	12.9	36
176	Antibody-secreting cells with a phenotype of Ki-67 <sup>low</sup> , CD138 <sup>high</sup> , CD31 <sup>high</sup> , and CD38 <sup>high</sup> secrete nonspecific IgM during primary hepatitis A virus infection. <i>Journal of Immunology</i> , <b>2013</b> , 191, 127-34	5.3	10
175	Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , <b>2013</b> , 6, 755-9	4.4	8
174	Transient elastography-based risk estimation of hepatitis B virus-related occurrence of hepatocellular carcinoma: development and validation of a predictive model. <i>OncoTargets and Therapy</i> , <b>2013</b> , 6, 1463-9	4.4	18
173	Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma. <i>Yonsei Medical Journal</i> , <b>2013</b> , 54, 1178-85	3	25
172	Predictors of refractory ascites development in patients with hepatitis B virus-related cirrhosis hospitalized to control ascitic decompensation. <i>Yonsei Medical Journal</i> , <b>2013</b> , 54, 145-53	3	3
171	Abnormal liver stiffness assessed using transient elastography (Fibroscan®) in HIV-infected patients without HBV/HCV coinfection receiving combined antiretroviral treatment. <i>PLoS ONE</i> , <b>2013</b> , 8, e52720	3.7	17
170	Investigation of oncogenic cooperation in simple liver-specific transgenic mouse models using noninvasive in vivo imaging. <i>PLoS ONE</i> , <b>2013</b> , 8, e59869	3.7	27
169	Association between IL28B polymorphisms and spontaneous clearance of hepatitis B virus infection. <i>PLoS ONE</i> , <b>2013</b> , 8, e69166	3.7	23

168	Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma. <i>PLoS ONE</i> , <b>2013</b> , 8, e77240	3.7	19
167	Discordance between liver biopsy and FibroTest in assessing liver fibrosis in chronic hepatitis B. <i>PLoS ONE</i> , <b>2013</b> , 8, e55759	3.7	10
166	Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , <b>2013</b> , 19, 82-6	6.9	11
165	Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , <b>2013</b> , 19, 399-408	6.9	2
164	Characterization of focal liver masses using acoustic radiation force impulse elastography. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 219-26	5.6	41
163	Quasispecies and pre-existing drug-resistant mutations of hepatitis B virus in patients with chronic hepatitis B. <i>Gut and Liver</i> , <b>2013</b> , 7, 329-34	4.8	11
162	Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 1343-50	6.1	70
161	"Normal" liver stiffness values differ between men and women: a prospective study for healthy living liver and kidney donors in a native Korean population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2012</b> , 27, 781-8	4	27
160	Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2012</b> , 27, 1528-34	4	13
159	CD11b(+) Gr1(+) bone marrow cells ameliorate liver fibrosis by producing interleukin-10 in mice. <i>Hepatology</i> , <b>2012</b> , 56, 1902-12	11.2	51
158	Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in predicting treatment response in unresectable hepatocellular carcinoma patients treated with external beam radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2012</b> , 82, 1172-8	4	23
157	Prediction of recurrence after curative resection of hepatocellular carcinoma using liver stiffness measurement (FibroScan®). <i>Annals of Surgical Oncology</i> , <b>2012</b> , 19, 4278-86	3.1	54
156	Predictive value of HBsAg quantification for determining the clinical course of genotype C HBeAg-negative carriers. <i>Liver International</i> , <b>2012</b> , 32, 796-802	7.9	27
155	The significance of ICG-R15 in predicting hepatic toxicity in patients receiving radiotherapy for hepatocellular carcinoma. <i>Liver International</i> , <b>2012</b> , 32, 1165-71	7.9	13
154	Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma. <i>Liver International</i> , <b>2012</b> , 32, 1120-7	7.9	83
153	The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis. <i>Journal of Hepatology</i> , <b>2012</b> , 57, 556-63	13.4	101
152	No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations. <i>BMC Medical Genetics</i> , <b>2012</b> , 13, 47	2.1	34
151	Clinical features and prognosis of hepatocellular carcinoma in Mongolia: a multicentre study. <i>Hepatology International</i> , <b>2012</b> , 6, 763-9	8.8	22

150	Serum cytokine levels in chronic hepatitis B patients receiving peginterferon alpha-2a therapy. <i>Hepatobiliary and Pancreatic Diseases International</i> , <b>2012</b> , 11, 499-506	2.1	9
149	Clinical characteristics of acute hepatitis A complicated by acute kidney injury. <i>Scandinavian Journal of Infectious Diseases</i> , <b>2012</b> , 44, 144-8		3
148	Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate. <i>Arthritis Research and Therapy</i> , <b>2012</b> , 14, R232	5.7	34
147	Discordance between liver biopsy and Fibroscan <sup>®</sup> in assessing liver fibrosis in chronic hepatitis b: risk factors and influence of necroinflammation. <i>PLoS ONE</i> , <b>2012</b> , 7, e32233	3.7	43
146	Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B. <i>PLoS ONE</i> , <b>2012</b> , 7, e35825	3.7	44
145	How many valid measurements are necessary to assess liver fibrosis using FibroScan <sup>®</sup> in patients with chronic viral hepatitis? An analysis of subjects with at least 10 valid measurements. <i>Yonsei Medical Journal</i> , <b>2012</b> , 53, 337-45	3	11
144	Spontaneous bacterial peritonitis in patients with hepatitis B virus-related liver cirrhosis: community-acquired versus nosocomial. <i>Yonsei Medical Journal</i> , <b>2012</b> , 53, 328-36	3	7
143	Combined measurement of preoperative $\alpha$ -fetoprotein and des- $\gamma$ -carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma. <i>International Journal of Cancer</i> , <b>2012</b> , 131, 2332-41	7.5	26
142	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. <i>Hepatology International</i> , <b>2012</b> , 6, 531-61	8.8	768
141	Liver stiffness measurement using acoustic radiation force impulse (ARFI) elastography and effect of necroinflammation. <i>Digestive Diseases and Sciences</i> , <b>2012</b> , 57, 1682-91	4	73
140	Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study. <i>Investigational New Drugs</i> , <b>2012</b> , 30, 1150-7	4.3	8
139	Normal liver elasticity values using acoustic radiation force impulse imaging: a prospective study in healthy living liver and kidney donors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2012</b> , 27, 130-6	4	42
138	Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2012</b> , 27, 313-22	4	29
137	Combination of preS deletions and A1762T/G1764A mutations in HBV subgenotype C2 increases the risk of developing HCC. <i>Intervirology</i> , <b>2012</b> , 55, 296-302	2.5	10
136	Risk assessment of development of hepatic decompensation in histologically proven hepatitis B viral cirrhosis using liver stiffness measurement. <i>Digestion</i> , <b>2012</b> , 85, 219-27	3.6	17
135	Prediction of esophageal variceal bleeding in B-viral liver cirrhosis using the P2/MS noninvasive index based on complete blood counts. <i>Digestion</i> , <b>2012</b> , 86, 264-72	3.6	2
134	Epidemiology and surveillance of hepatocellular carcinoma. <i>Liver Cancer</i> , <b>2012</b> , 1, 2-14	9.1	124
133	How to improve treatment outcomes for hepatocellular carcinoma of intermediate and advanced stage. <i>Digestive Diseases</i> , <b>2012</b> , 30, 598-602	3.2	16

132	Optimal time for restoring the reliability of liver stiffness measurement in patients with chronic hepatitis B experiencing acute exacerbation. <i>Journal of Clinical Gastroenterology</i> , <b>2012</b> , 46, 602-7	3	12
131	The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B. <i>Journal of Clinical Gastroenterology</i> , <b>2012</b> , 46, 518-25	3	48
130	Acoustic radiation force impulse elastography: a better option for patients with extrahepatic cholestasis. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2012</b> , 24, 215-6	2.2	5
129	Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2012</b> , 24, 849-56	2.2	30
128	A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudine. <i>Antiviral Therapy</i> , <b>2012</b> , 17, 1563-70	1.6	12
127	Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis. <i>PLoS ONE</i> , <b>2012</b> , 7, e36676	3.7	76
126	Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean. <i>PLoS ONE</i> , <b>2012</b> , 7, e39175	3.7	117
125	Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B. <i>PLoS ONE</i> , <b>2012</b> , 7, e41964	3.7	59
124	Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. <i>PLoS ONE</i> , <b>2012</b> , 7, e44930	3.7	202
123	Hepatocellular carcinoma in Budd-Chiari syndrome: a single center experience with long-term follow-up in South Korea. <i>World Journal of Gastroenterology</i> , <b>2012</b> , 18, 1946-52	5.6	34
122	Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. <i>Oncology</i> , <b>2011</b> , 81 Suppl 1, 158-64	3.6	93
121	Hepatitis B virus serology to predict antiviral response in chronic hepatitis B. <i>Digestion</i> , <b>2011</b> , 84 Suppl 1, 29-34	3.6	6
120	Antifibrotic effects of magnesium lithospermate B on hepatic stellate cells and thioacetamide-induced cirrhotic rats. <i>Experimental and Molecular Medicine</i> , <b>2011</b> , 43, 341-9	12.8	30
119	Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 2568-75	7.5	50
118	Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. <i>Lancet Oncology</i> , <b>2011</b> , 12, 568-74	21.7	427
117	Gastroduodenal complications after concurrent chemoradiation therapy in patients with hepatocellular carcinoma: endoscopic findings and risk factors. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 81, 1343-51	4	34
116	Clinicopathological characteristics in combined hepatocellular-cholangiocarcinoma: a single center study in Korea. <i>Yonsei Medical Journal</i> , <b>2011</b> , 52, 753-60	3	25
115	Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B. <i>Antiviral Therapy</i> , <b>2011</b> , 16, 469-77	1.6	19

114	The usefulness of liver stiffness measurement using FibroScan in chronic hepatitis C in South Korea: a multicenter, prospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2011</b> , 26, 171-84		33
113	Non-invasive assessment of liver fibrosis: the gap between ideal and real. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2011</b> , 26, 937-9	4	4
112	Early Efetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma. <i>Liver International</i> , <b>2011</b> , 31, 369-76	7.9	50
111	Predictive factors for long-term survival in patients with clinically significant portal hypertension following resection of hepatocellular carcinoma. <i>Liver International</i> , <b>2011</b> , 31, 485-93	7.9	33
110	A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. <i>Liver International</i> , <b>2011</b> , 31 Suppl 2, 61-80	7.9	412
109	Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. <i>Liver International</i> , <b>2011</b> , 31, 1144-9	7.9	50
108	Treatment of recurrent hepatocellular carcinoma after liver transplantation. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2011</b> , 7, 258-69	1.9	9
107	Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2011</b> , 137, 659-67	4.9	43
106	Clinical features and prognosis of hepatocellular carcinoma with respect to pre-S deletion and basal core promoter mutations of hepatitis B virus Genotype C2. <i>Journal of Medical Virology</i> , <b>2011</b> , 83, 2088-95	19.7	8
105	Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). <i>Hepatology</i> , <b>2011</b> , 53, 885-94	11.2	285
104	Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. <i>Hepatology</i> , <b>2011</b> , 53, 1486-93	11.2	110
103	18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. <i>Cancer</i> , <b>2011</b> , 117, 4779-87	6.4	45
102	Serum cytokine levels in patients with chronic hepatitis B according to lamivudine therapy. <i>Journal of Clinical Laboratory Analysis</i> , <b>2011</b> , 25, 414-21	3	11
101	Risk assessment of esophageal variceal bleeding in B-viral liver cirrhosis by a liver stiffness measurement-based model. <i>American Journal of Gastroenterology</i> , <b>2011</b> , 106, 1654-62, 1730	0.7	48
100	Prevention of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. <i>Oncology</i> , <b>2011</b> , 81 Suppl 1, 41-9	3.6	32
99	Current situation of hepatocellular carcinoma in Mongolia. <i>Oncology</i> , <b>2011</b> , 81 Suppl 1, 148-51	3.6	22
98	Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma. <i>Oncology</i> , <b>2011</b> , 81, 184-91	3.6	16
97	Impact of hepatitis B virus (HBV) x gene mutations on hepatocellular carcinoma development in chronic HBV infection. <i>Vaccine Journal</i> , <b>2011</b> , 18, 914-21		44

96	Final Results of Open-Label Treatment with Eltrombopag During ENABLE 1: A Study of Eltrombopag As An Adjunct for Antiviral Treatment of Hepatitis C Virus Associated with Thrombocytopenia. <i>Blood</i> , <b>2011</b> , 118, 2232-2232	2.2	4
95	Prediction of significant fibrosis in chronic hepatitis C patients with normal ALT. <i>Hepato-Gastroenterology</i> , <b>2011</b> , 58, 1321-7		6
94	Clinical characteristics and treatment outcomes of hepatocellular carcinoma with inferior vena cava/heart invasion. <i>Anticancer Research</i> , <b>2011</b> , 31, 4641-6	2.3	18
93	What are the true normal liver stiffness values using FibroScan?: a prospective study in healthy living liver and kidney donors in South Korea. <i>Liver International</i> , <b>2010</b> , 30, 268-74	7.9	62
92	Prospective validation of P2/MS noninvasive index using complete blood counts for detecting oesophageal varices in B-viral cirrhosis. <i>Liver International</i> , <b>2010</b> , 30, 860-6	7.9	13
91	A novel liver stiffness measurement-based prediction model for cirrhosis in hepatitis B patients. <i>Liver International</i> , <b>2010</b> , 30, 1073-81	7.9	29
90	Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion. <i>Liver International</i> , <b>2010</b> , 30, 1427-38	7.9	32
89	Ascitic fluid infection in patients with hepatitis B virus-related liver cirrhosis: culture-negative neutrocytic ascites versus spontaneous bacterial peritonitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2010</b> , 25, 122-8	4	30
88	Systemic treatment in advanced/metastatic hepatocellular carcinoma in the era of targeted therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2010</b> , 25, 1023-5	4	5
87	Non-invasive assessment of liver fibrosis: time to move from cross-sectional studies to longitudinal ones. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2010</b> , 25, 1472-3	4	10
86	Transient elastography in chronic hepatitis B: an Asian perspective. <i>World Journal of Gastroenterology</i> , <b>2010</b> , 16, 5173-80	5.6	28
85	Clinical efficacy of a 24-months course of lamivudine therapy in patients with HBeAg negative chronic hepatitis B: a long-term prospective study. <i>Journal of Korean Medical Science</i> , <b>2010</b> , 25, 882-7	4.7	13
84	A liver stiffness measurement-based, noninvasive prediction model for high-risk esophageal varices in B-viral liver cirrhosis. <i>American Journal of Gastroenterology</i> , <b>2010</b> , 105, 1382-90	0.7	159
83	Positioning and indication of sorafenib in the treatment algorithm and real practice setting: Western and eastern approach--Asian perspective. <i>Oncology</i> , <b>2010</b> , 78 Suppl 1, 167-71	3.6	10
82	New automated hepatitis C virus (HCV) core antigen assay as an alternative to real-time PCR for HCV RNA quantification. <i>Journal of Clinical Microbiology</i> , <b>2010</b> , 48, 2253-6	9.7	79
81	Identification of proteins indicating radiation-induced hepatic toxicity in cirrhotic rats. <i>Journal of Radiation Research</i> , <b>2010</b> , 51, 643-50	2.4	12
80	Autologous bone marrow infusion activates the progenitor cell compartment in patients with advanced liver cirrhosis. <i>Cell Transplantation</i> , <b>2010</b> , 19, 1237-46	4	71
79	How can we enhance the performance of liver stiffness measurement using FibroScan in diagnosing liver cirrhosis in patients with chronic hepatitis B?. <i>Journal of Clinical Gastroenterology</i> , <b>2010</b> , 44, 66-71	3	88

78	Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. <i>Antiviral Therapy</i> , <b>2010</b> , 15, 145-55	1.6	37
77	Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. <i>Antiviral Therapy</i> , <b>2010</b> , 15, 235-41	1.6	59
76	Treatment of chronic hepatitis B in Asia-Pacific countries: is the Asia-Pacific consensus statement being followed?. <i>Antiviral Therapy</i> , <b>2010</b> , 15, 607-16	1.6	9
75	Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression. <i>Hepatology International</i> , <b>2010</b> , 4, 673-80	8.8	37
74	Association between polymorphism of tumor necrosis factor-alpha promoter and response to lamivudine treatment in patients with chronic hepatitis B. <i>Digestive Diseases and Sciences</i> , <b>2010</b> , 55, 2043-8	4.8	5
73	Comparison of surrogate serum markers and transient elastography (Fibroscan) for assessing cirrhosis in patients with chronic viral hepatitis. <i>Digestive Diseases and Sciences</i> , <b>2010</b> , 55, 3552-60	4	35
72	Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. <i>Hepatology</i> , <b>2010</b> , 51, 415-21	11.2	91
71	Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease. <i>Hepatology</i> , <b>2010</b> , 51, 767-76	11.2	36
70	Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. <i>Hepatology</i> , <b>2010</b> , 52, 886-93	11.2	692
69	Surgical resection for pulmonary metastasis from hepatocellular carcinoma: analysis of prognosis in relation to primary control. <i>Journal of Surgical Oncology</i> , <b>2010</b> , 101, 239-43	2.8	20
68	Molecular and clinical characteristics of hepatitis B virus in Korea. <i>Journal of Medical Virology</i> , <b>2010</b> , 82, 1126-34	19.7	30
67	Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. <i>Journal of Medical Virology</i> , <b>2010</b> , 82, 1835-42	19.7	45
66	Can preoperative diffusion-weighted MRI predict postoperative hepatic insufficiency after curative resection of HBV-related hepatocellular carcinoma? A pilot study. <i>Magnetic Resonance Imaging</i> , <b>2010</b> , 28, 802-11	3.3	14
65	Effects of the knockdown of hypoxia inducible factor-1 expression by adenovirus-mediated shRNA on angiogenesis and tumor growth in hepatocellular carcinoma cell lines. <i>The Korean Journal of Hepatology</i> , <b>2010</b> , 16, 280-7		12
64	A case of embryonal sarcoma of the liver mimicking a hydatid cyst in an adult. <i>Gut and Liver</i> , <b>2010</b> , 4, 245-8	4.8	10
63	The impact of steatosis on liver stiffness measurement in patients with chronic hepatitis B. <i>Hepato-Gastroenterology</i> , <b>2010</b> , 57, 832-8		7
62	Preoperative radiologic and postoperative pathologic risk factors for early intra-hepatic recurrence in hepatocellular carcinoma patients who underwent curative resection. <i>Yonsei Medical Journal</i> , <b>2009</b> , 50, 789-95	3	22
61	The efficacy of hepatic resection after neoadjuvant transarterial chemoembolization (TACE) and radiation therapy in hepatocellular carcinoma greater than 5 cm in size. <i>Journal of Korean Medical Science</i> , <b>2009</b> , 24, 242-7	4.7	22

60	Hepatitis B e antigen-negative mutations in the precore and core promoter regions in Korean patients. <i>Journal of Medical Virology</i> , <b>2009</b> , 81, 594-601	19.7	15
59	Specific mutations in the enhancer II/core promoter/precore regions of hepatitis B virus subgenotype C2 in Korean patients with hepatocellular carcinoma. <i>Journal of Medical Virology</i> , <b>2009</b> , 81, 1002-8	19.7	45
58	Usefulness of FibroScan for detection of early compensated liver cirrhosis in chronic hepatitis B. <i>Digestive Diseases and Sciences</i> , <b>2009</b> , 54, 1758-63	4	115
57	Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2009</b> , 24, 955-61	4	55
56	Ascites and spontaneous bacterial peritonitis: an Asian perspective. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2009</b> , 24, 1494-503	4	24
55	Liver stiffness measurement using FibroScan is influenced by serum total bilirubin in acute hepatitis. <i>Liver International</i> , <b>2009</b> , 29, 810-5	7.9	41
54	Variability in liver stiffness values from different intercostal spaces. <i>Liver International</i> , <b>2009</b> , 29, 760-6	7.9	15
53	Can microvessel invasion of hepatocellular carcinoma be predicted by pre-operative MRI?. <i>European Radiology</i> , <b>2009</b> , 19, 1744-51	8	118
52	Outcome after curative resection for a huge ( $\geq 10$ cm) hepatocellular carcinoma and prognostic significance of gross tumor classification. <i>American Journal of Surgery</i> , <b>2009</b> , 198, 693-701	2.7	77
51	Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. <i>Scandinavian Journal of Gastroenterology</i> , <b>2009</b> , 44, 861-6	2.4	33
50	Efficacy and safety of transarterial chemoembolization in recurrent hepatocellular carcinoma after curative surgical resection. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2009</b> , 32, 564-9	2.7	28
49	Recombinant interferon-Beta-1 alpha plus ribavirin for the treatment of chronic HCV infection: a prospective, randomized, comparative pilot study. <i>Gut and Liver</i> , <b>2009</b> , 3, 20-5	4.8	5
48	Rescue Monotherapy in Lamivudine-Resistant Hepatitis B e Antigen-Positive Chronic Hepatitis B: Adefovir versus Entecavir. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 705-712	1.6	19
47	Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: A prospective randomized, comparative pilot study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2008</b> , 23, 729-35	4	16
46	Chemotherapy for advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2008</b> , 23, 682-4	4	12
45	Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2008</b> , 23, 1722-7	4	29
44	Clinical course of virologic breakthrough after emergence of YMDD mutations in HBeAg-positive chronic hepatitis B. <i>Intervirology</i> , <b>2008</b> , 51, 293-8	2.5	7
43	New diagnostic method for liver fibrosis and cirrhosis. <i>Intervirology</i> , <b>2008</b> , 51 Suppl 1, 11-6	2.5	41



42	MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. <i>Carcinogenesis</i> , <b>2008</b> , 29, 1192-6	4.6	108
41	Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with chronic hepatitis B. <i>Journal of Clinical Gastroenterology</i> , <b>2008</b> , 42, 738-43	3	25
40	Hepatic splenosis preoperatively diagnosed as hepatocellular carcinoma in a patient with chronic hepatitis B: a case report. <i>Journal of Korean Medical Science</i> , <b>2008</b> , 23, 336-41	4.7	26
39	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. <i>Hepatology International</i> , <b>2008</b> , 2, 263-83	8.8	761
38	Prediction of postoperative hepatic insufficiency by liver stiffness measurement (FibroScan((R))) before curative resection of hepatocellular carcinoma: a pilot study. <i>Hepatology International</i> , <b>2008</b> , 2, 471-7	8.8	66
37	Hepatocellular carcinoma presenting with bone metastasis: clinical characteristics and prognostic factors. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2008</b> , 134, 1377-84	4.9	59
36	Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. <i>Cancer</i> , <b>2008</b> , 113, 995-1003	6.4	128
35	Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. <i>Gastroenterology</i> , <b>2007</b> , 133, 1437-44	13.3	283
34	Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. <i>Cancer</i> , <b>2007</b> , 110, 129-37	6.4	85
33	Clinical outcome of renal transplantation in patients with positive pre-transplant hepatitis B surface antigen. <i>Journal of Medical Virology</i> , <b>2007</b> , 79, 1655-63	19.7	46
32	Long-term outcome of chronic hepatitis B based on histological grade and stage. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2007</b> , 22, 383-8	4	66
31	Noninvasive models to predict liver cirrhosis in patients with chronic hepatitis B. <i>Liver International</i> , <b>2007</b> , 27, 969-76	7.9	80
30	Liver cancer in Korea. <i>Hepatology Research</i> , <b>2007</b> , 37 Suppl 2, S106-9	5.1	16
29	What is the role of diagnostic laparoscopy in a gastroenterology unit?. <i>Journal of Gastroenterology</i> , <b>2007</b> , 42, 881-6	6.9	8
28	Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma. <i>Oncology</i> , <b>2007</b> , 72 Suppl 1, 104-10	3.6	89
27	Changes in serum and ascitic monocyte chemotactic protein-1 (MCP-1) and IL-10 levels in cirrhotic patients with spontaneous bacterial peritonitis. <i>Journal of Interferon and Cytokine Research</i> , <b>2007</b> , 27, 227-30	3.5	26
26	MRP2 haplotypes confer differential susceptibility to toxic liver injury. <i>Pharmacogenetics and Genomics</i> , <b>2007</b> , 17, 403-15	1.9	119
25	Association of genetic variations in CCR5 and its ligand, RANTES with clearance of hepatitis B virus in Korea. <i>Journal of Medical Virology</i> , <b>2006</b> , 78, 1564-71	19.7	35

24	Long-term clinical outcome of phase IIb clinical trial of percutaneous injection with holmium-166/chitosan complex (Milican) for the treatment of small hepatocellular carcinoma. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 543-8	12.9	72
23	A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. <i>New England Journal of Medicine</i> , <b>2006</b> , 354, 1001-10	59.2	1146
22	Efficacy and long-term follow up of combination therapy with interferon alpha and ribavirin for chronic hepatitis C in Korea. <i>Yonsei Medical Journal</i> , <b>2006</b> , 47, 793-8	3	6
21	Hepatic stellate cells primed with cytokines upregulate inflammation in response to peptidoglycan or lipoteichoic acid. <i>Laboratory Investigation</i> , <b>2006</b> , 86, 676-86	5.9	63
20	The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B. <i>Antiviral Therapy</i> , <b>2006</b> , 11, 447-55	1.6	7
19	The Clinical Impact of Early Detection of the Ymdd Mutant on the Outcomes of Long-Term Lamivudine Therapy in Patients with Chronic Hepatitis B. <i>Antiviral Therapy</i> , <b>2006</b> , 11, 447-455	1.6	27
18	Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. <i>Journal of Hepatology</i> , <b>2005</b> , 42, 188-94	13.4	151
17	Usefulness of urine strip test in the rapid diagnosis of spontaneous bacterial peritonitis. <i>Liver International</i> , <b>2005</b> , 25, 1197-201	7.9	27
16	Long-term clinical outcome of large volume paracentesis with intravenous albumin in patients with spontaneous bacterial peritonitis: a randomized prospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2005</b> , 20, 1215-22	4	16
15	Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. <i>Yonsei Medical Journal</i> , <b>2005</b> , 46, 399-407	3	94
14	How to predict HCC development in patients with chronic B viral liver disease?. <i>Intervirolgy</i> , <b>2005</b> , 48, 23-8	2.5	45
13	Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. <i>Antiviral Therapy</i> , <b>2005</b> , 10, 441-9	1.6	25
12	Evaluation of Methods for Monitoring Drug Resistance in Chronic Hepatitis B Patients during Lamivudine Therapy Based on Mass Spectrometry and Reverse Hybridization. <i>Antiviral Therapy</i> , <b>2005</b> , 10, 441-449	1.6	55
11	Hepatitis B virus infection after renal transplantation in the presence of antibody to hepatitis B surface antigen immunity. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2004</b> , 19, 847-53	4	11
10	Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2004</b> , 31, 1621-30	8.8	67
9	Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy. <i>Journal of Medical Virology</i> , <b>2003</b> , 71, 367-75	19.7	32
8	Factors predictive of response to interferon-alpha therapy in hepatitis C virus type 1b infection. <i>Journal of Medical Virology</i> , <b>2002</b> , 66, 481-7	19.7	11
7	Immunogenetics of hepatitis B virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2002</b> , 17 Suppl 3, S329-32	4	3

6	Treatment of non-resectable hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2002</b> , 17 Suppl 3, S424-7	4	14
5	Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea. <i>Journal of Hepatology</i> , <b>2001</b> , 35, 92-8	13.4	34
4	Association between hepatitis B virus infection and HLA-DR type in Korea. <i>Hepatology</i> , <b>2000</b> , 31, 1371-3	11.2	103
3	The Efficacy of the Ultrasonographic Screening Test for Early Detection of Hepatocellular Carcinoma and Risk Factors of HCC in Korea <b>2000</b> , 1-9		3
2	Nucleotide sequence variation in the hypervariable region of the hepatitis C virus in the sera of chronic hepatitis C patients undergoing controlled interferon-alpha therapy. <i>Journal of Medical Virology</i> , <b>1996</b> , 49, 95-102	19.7	21
1	Nucleotide sequence variation in the hypervariable region of the hepatitis C virus in the sera of chronic hepatitis C patients undergoing controlled interferon- $\alpha$ therapy <b>1996</b> , 49, 95		1